Which type of targeted therapy drug does Enasidenib belong to?

Enasidenib is an oral targeted therapy for isocitrate dehydrogenase type 2 (IDH2) mutations. IDH2Gene mutations are common in some patients with acute myeloid leukemia (AML). This mutation leads to abnormal cell metabolism and promotes the proliferation and survival of cancer cells. Ensidipine specifically inhibits the activity of mutant IDH2 enzyme and blocks the production of abnormal metabolites, thereby inhibiting the growth of tumor cells and promoting their differentiation.

As a targeted inhibitor, ensidipine has a relatively precise mechanism of action and specifically targets cancer subtypes driven by IDH2 mutations, which is different from traditional chemotherapy drugs. It helps restore normal cell differentiation processes and reduces the number of malignant cells by reversing metabolic abnormalities. This targeted treatment method not only improves the efficacy, but also reduces the damage to normal cells, has relatively mild side effects, and improves the patient's quality of life.

Clinical trial data show that ensidipine has a good therapeutic effect in patients with IDH2 mutation-positive acute myeloid leukemia. Many patients have significantly reduced tumor burden after receiving treatment, and some patients achieve complete remission. The drug brings new treatment hope to patients for whom traditional therapies have limited efficacy, and also promotes the development of molecularly targeted treatments for AML.

In general, ensidipine, as an IDH2 mutation target inhibitor, is an important representative of modern precision medicine. By accurately identifying and inhibiting oncogene mutations, ensidipine provides personalized treatment options for AML patients. With the deepening of relevant research, ensidipine is expected to play an important role in more indications and treatment combinations in the future.

Reference materials:https://www.idhifa.com/